Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Expected to Rise, Barclays Analyst Says

Iovance Biotherapeutics (NASDAQ:IOVA) had its price objective hoisted by equities researchers at Barclays from $18.00 to $19.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective suggests a potential upside of 136.32% from the stock’s previous close.

IOVA has been the topic of a number of other reports. Citigroup reaffirmed an “outperform” rating on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. UBS Group increased their price objective on Iovance Biotherapeutics from $7.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. The Goldman Sachs Group assumed coverage on Iovance Biotherapeutics in a research report on Thursday, September 24th. They set a “buy” rating and a $15.00 price objective for the company. Zacks Research upgraded Iovance Biotherapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 26th. Finally, Wells Fargo & Company upped their target price on Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.80.

Iovance Biotherapeutics Stock Performance

Shares of IOVA opened at $8.04 on Friday. The company’s 50 day moving average price is $11.37 and its 200 day moving average price is $5.97. Iovance Biotherapeutics has a 52 week low of $2.08 and a 52 week high of $15.37. The company has a market capitalization of $3.64 billion, a PE ratio of -15.17 and a beta of 0.88.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The company had revenue of $121.47 million during the quarter, compared to the consensus estimate of $115.98 million. Iovance Biotherapeutics had a negative net margin of 58.20% and a negative return on equity of 30.68%. The company’s revenue was up 64.8% on a year-over-year basis. On average, equities analysts forecast that Iovance Biotherapeutics will post -0.43 earnings per share for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Iovance Biotherapeutics in the 2nd quarter worth $153,744,000. Palo Alto Investors LP bought a new stake in Iovance Biotherapeutics during the second quarter valued at about $22,032,229. Bank of America Corp DE bought a new stake in Iovance Biotherapeutics during the second quarter valued at about $20,773,000. Knott David M Jr bought a new stake in Iovance Biotherapeutics during the first quarter valued at about $5,616,000. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of Iovance Biotherapeutics in the second quarter valued at about $6,406,000. 77.03% of the stock is currently owned by institutional investors and hedge funds.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.